1006 related articles for article (PubMed ID: 14658949)
1. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study.
Bai YM; Yu SC; Lin CC
J Clin Psychiatry; 2003 Nov; 64(11):1342-8. PubMed ID: 14658949
[TBL] [Abstract][Full Text] [Related]
2. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
[TBL] [Abstract][Full Text] [Related]
3. A double-blind placebo-controlled study of vitamin E treatment of tardive dyskinesia.
Lohr JB; Caligiuri MP
J Clin Psychiatry; 1996 Apr; 57(4):167-73. PubMed ID: 8601552
[TBL] [Abstract][Full Text] [Related]
4. No difference in the effect of biperiden and amantadine on parkinsonian- and tardive dyskinesia-type involuntary movements: a double-blind crossover, placebo-controlled study in medicated chronic schizophrenic patients.
Silver H; Geraisy N; Schwartz M
J Clin Psychiatry; 1995 Apr; 56(4):167-70. PubMed ID: 7713856
[TBL] [Abstract][Full Text] [Related]
5. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
[TBL] [Abstract][Full Text] [Related]
6. Clinical effectiveness of the Kampo medicine kamishoyosan for adjunctive treatment of tardive dyskinesia in patients with schizophrenia: a 16-week open trial.
Lee JG; Shin BS; Lee YC; Park SW; Kim YH
Psychiatry Clin Neurosci; 2007 Oct; 61(5):509-14. PubMed ID: 17875029
[TBL] [Abstract][Full Text] [Related]
7. Effects of warm-supplementing kidney yang (WSKY) capsule added on risperidone on cognition in chronic schizophrenic patients: a randomized, double-blind, placebo-controlled, multi-center clinical trial.
Chen ZH; Wang GH; Wang XP; Chen RY; Wang HL; Yang MH; Huo YX; Mei HB
Hum Psychopharmacol; 2008 Aug; 23(6):465-70. PubMed ID: 18536066
[TBL] [Abstract][Full Text] [Related]
8. Risperidone for the treatment of acute mania in children and adolescents with bipolar disorder: a randomized, double-blind, placebo-controlled study.
Haas M; Delbello MP; Pandina G; Kushner S; Van Hove I; Augustyns I; Quiroz J; Kusumakar V
Bipolar Disord; 2009 Nov; 11(7):687-700. PubMed ID: 19839994
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of long-acting risperidone in schizophrenia: a 12-week, multicenter, open-label study in stable patients switched from typical and atypical oral antipsychotics.
Lindenmayer JP; Eerdekens E; Berry SA; Eerdekens M
J Clin Psychiatry; 2004 Aug; 65(8):1084-9. PubMed ID: 15323593
[TBL] [Abstract][Full Text] [Related]
10. The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: a double-blind placebo-controlled trial.
Zhang XY; Zhou DF; Cao LY; Xu CQ; Chen DC; Wu GY
J Clin Psychopharmacol; 2004 Feb; 24(1):83-6. PubMed ID: 14709952
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
12. Risperidone for pre-existing severe tardive dyskinesia: a 48-week prospective follow-up study.
Bai YM; Yu SC; Chen JY; Lin CY; Chou P; Lin CC
Int Clin Psychopharmacol; 2005 Mar; 20(2):79-85. PubMed ID: 15729082
[TBL] [Abstract][Full Text] [Related]
13. Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety.
Sheehan DV; McElroy SL; Harnett-Sheehan K; Keck PE; Janavs J; Rogers J; Gonzalez R; Shivakumar G; Suppes T
J Affect Disord; 2009 Jun; 115(3):376-85. PubMed ID: 19042026
[TBL] [Abstract][Full Text] [Related]
14. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders.
Shea S; Turgay A; Carroll A; Schulz M; Orlik H; Smith I; Dunbar F
Pediatrics; 2004 Nov; 114(5):e634-41. PubMed ID: 15492353
[TBL] [Abstract][Full Text] [Related]
15. Risperidone in treatment-refractory schizophrenia.
Wirshing DA; Marshall BD; Green MF; Mintz J; Marder SR; Wirshing WC
Am J Psychiatry; 1999 Sep; 156(9):1374-9. PubMed ID: 10484947
[TBL] [Abstract][Full Text] [Related]
16. [Utility of quetiapine in tardive dyskinesia].
Navarro Pacheco BV; Montejo González AL; Martín Carrasco M
Actas Esp Psiquiatr; 2003; 31(6):347-52. PubMed ID: 14639511
[TBL] [Abstract][Full Text] [Related]
17. Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone.
Jeste DV; Okamoto A; Napolitano J; Kane JM; Martinez RA
Am J Psychiatry; 2000 Jul; 157(7):1150-5. PubMed ID: 10873925
[TBL] [Abstract][Full Text] [Related]
18. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol.
Smulevich AB; Khanna S; Eerdekens M; Karcher K; Kramer M; Grossman F
Eur Neuropsychopharmacol; 2005 Jan; 15(1):75-84. PubMed ID: 15572276
[TBL] [Abstract][Full Text] [Related]
19. Yi-gan san for the treatment of neuroleptic-induced tardive dyskinesia: an open-label study.
Miyaoka T; Furuya M; Yasuda H; Hayashida M; Nishida A; Inagaki T; Horiguchi J
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):761-4. PubMed ID: 18201810
[TBL] [Abstract][Full Text] [Related]
20. A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.
Chan HY; Chiang SC; Chang CJ; Gau SS; Chen JJ; Chen CH; Hwu HG; Lai MS
J Clin Psychiatry; 2010 Sep; 71(9):1226-33. PubMed ID: 20441726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
